SURGE THERAPEUTICS
LIVE

Serial Number

97042717

Owner

SURGE THERAPEUTICS, INC.

Attorney

Sara M. Bauer

First Use Date

Feb 4, 2026

Filing Date

Sep 23, 2021

Add to watchlist:

No watchlists yet
View on USPTO

SURGE THERAPEUTICS Trademark

Serial Number: 97042717

SURGE THERAPEUTICS is a trademark filed by SURGE THERAPEUTICS, INC. on September 23, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently pending registration.

Owner Contact Info

SURGE THERAPEUTICS, INC. (3 trademarks)

20 CHAPEL STREET
BROOKLINE, MA 02446

Entity Type: 03

STIMIT CORPORATION (2 trademarks)

B712
Brookline, MA 02446

Entity Type: 03

Trademark Details

Filing Date

September 23, 2021

Registration Date

Not Registered

First Use Anywhere

February 4, 2026

First Use in Commerce

February 4, 2026

Published for Opposition

February 27, 2024

Goods & Services

Artificial biomaterial for delivery of immunotherapy; Artificial intraoperative biomaterial for delivery of immunotherapy

Hydrogel for medical purposes; Natural biomaterial for delivery of immunotherapy; pharmaceutical preparations used to modulate an immune response; pharmaceutical preparations for the treatment of cancer and for enhancing immune response to tumors; therapeutic agents for impacting immune-stimulating cells; therapeutic agents for impacting immune-suppressive cells; pharmaceutical preparations for the prevention and treatment of oncological, viral, musculoskeletal, immune, autoimmune, blood, respiratory, metabolic, neurological, urological, neoplastic, fibrotic diseases and disorders, and pain; biological preparations for the prevention and treatment of oncological, viral, musculoskeletal, immune, autoimmune, blood, respiratory, metabolic, neurological, urological, neoplastic, fibrotic diseases and disorders, and pain; drug delivery agents in the form of injections for medical purposes for the prevention and treatment of oncological, viral, musculoskeletal, immune, autoimmune, blood, respiratory, metabolic, neurological, urological, neoplastic, fibrotic diseases and disorders, and pain; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical preparations, namely, biomaterials to extend the release of immunotherapy treatments at the site of tumor resection; Natural intraoperative biomaterial for delivery of immunotherapy

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 8, 2026 EXRA
SOU EXTENSION 4 GRANTED
Aug 7, 2026 EX4G
STATEMENT OF USE PROCESSING COMPLETE
Aug 7, 2026 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 7, 2026 AITU
SOU EXTENSION 4 FILED
Apr 21, 2026 EXT4
SOU TEAS EXTENSION RECEIVED
Apr 21, 2026 EEXT
USE AMENDMENT FILED
Mar 1, 2026 IUAF
TEAS STATEMENT OF USE RECEIVED
Mar 1, 2026 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 16, 2025 EXRA
SOU EXTENSION 3 GRANTED
Oct 15, 2025 EX3G
SOU EXTENSION 3 FILED
Oct 15, 2025 EXT3
SOU TEAS EXTENSION RECEIVED
Oct 15, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 16, 2025 EXRA
SOU EXTENSION 2 GRANTED
Apr 16, 2025 EX2G
SOU EXTENSION 2 FILED
Apr 16, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Apr 16, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 8, 2024 EXRA
SOU EXTENSION 1 GRANTED
Oct 8, 2024 EX1G
SOU EXTENSION 1 FILED
Oct 8, 2024 EXT1
SOU TEAS EXTENSION RECEIVED
Oct 8, 2024 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 23, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 4, 2024 NPUB
PUBLISHED FOR OPPOSITION
Feb 27, 2024 PUBO
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 7, 2024 NPUB
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 7, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 24, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 24, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 24, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 24, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 24, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 28, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 27, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 27, 2023 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 27, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 27, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 27, 2023 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 27, 2023 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 27, 2023 COAR
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Aug 25, 2023 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Aug 25, 2023 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 30, 2023 GNRN
NON-FINAL ACTION E-MAILED
Jun 30, 2023 GNRT
NON-FINAL ACTION WRITTEN
Jun 30, 2023 CNRT
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jun 8, 2023 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Nov 25, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Nov 25, 2022 GNSL
SUSPENSION LETTER WRITTEN
Nov 25, 2022 CNSL
EXAMINER'S AMENDMENT ENTERED
Nov 14, 2022 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 14, 2022 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 14, 2022 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 14, 2022 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 22, 2022 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 21, 2022 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 21, 2022 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 21, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jul 21, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jul 21, 2022 CNRT
ASSIGNED TO EXAMINER
Jun 24, 2022 DOCK
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Nov 3, 2021 ASGN
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 26, 2021 NWOS
NEW APPLICATION ENTERED
Sep 27, 2021 NWAP